Free Trial

Beigene 2/27/2025 Earnings Report

Beigene logo
$242.75 +12.39 (+5.38%)
As of 04/14/2025 04:00 PM Eastern

Beigene EPS Results

Actual EPS
-$1.43
Consensus EPS
-$0.88
Beat/Miss
Missed by -$0.55
One Year Ago EPS
N/A

Beigene Revenue Results

Actual Revenue
$1.13 billion
Expected Revenue
$1.09 billion
Beat/Miss
Beat by +$40.85 million
YoY Revenue Growth
N/A

Beigene Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Remove Ads

Beigene Earnings Headlines

Guggenheim Reiterates Buy Rating for Beigene (NASDAQ:ONC)
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Beigene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beigene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beigene and other key companies, straight to your email.

About Beigene

Beigene (NASDAQ:ONC) Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

View Beigene Profile

More Earnings Resources from MarketBeat